Curated insights • How it Works • Practical Pearls • Evidence Base
Validated in patients with non-valvular atrial fibrillation. Should be used in conjunction with stroke risk assessment scores (e.g., CHA2DS2-VASc).
| H: Hypertension (SBP > 160) |
| A: Abnormal Renal/Liver Function |
| S: Stroke History |
| B: Bleeding History/Anemia |
| L: Labile INR (if on Warfarin) |
| E: Elderly (Age > 65) |
| D: Drugs (NSAIDs/ASA) or Alcohol |
| Score 0-2 |
| Score ≥ 3 |
The score aggregates major physiological and lifestyle predictors of haemorrhage. Hypertension and prior stroke reflect underlying vascular fragility, while renal/liver dysfunction impairs coagulation factor synthesis and drug clearance.
A high HAS-BLED score is NOT a reason to withhold anticoagulation. Instead, it identifies the patient who needs more frequent monitoring and more aggressive management of modifiable risks. In most high-risk patients, the benefit of stroke prevention still far outweighs the risk of major bleeding.
While HAS-BLED is mnemonic-based and easy to use at the bedside, newer biomarker-based scores like the ABC (Age, Biomarkers, Clinical history) score are now considered more accurate if hs-Troponin and GDF-15 are available.
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation.
Formally recommended by the European Society of Cardiology (ESC) and several other international societies for routine bleeding risk assessment.
Dutch cardiologist who developed the score as part of his research into stroke prevention and bleeding risk in atrial fibrillation management.
The score was developed to replace older, more complex bleeding risk models that were difficult to use in daily clinical practice. HAS-BLED was specifically designed to be mnemonic-friendly.
HAS-BLED: Estimates major bleeding risk for patients on anticoagulation for AF.
Curated insights • How it Works • Practical Pearls • Evidence Base
Validated in patients with non-valvular atrial fibrillation. Should be used in conjunction with stroke risk assessment scores (e.g., CHA2DS2-VASc).
| H: Hypertension (SBP > 160) |
| A: Abnormal Renal/Liver Function |
| S: Stroke History |
| B: Bleeding History/Anemia |
| L: Labile INR (if on Warfarin) |
| E: Elderly (Age > 65) |
| D: Drugs (NSAIDs/ASA) or Alcohol |
| Score 0-2 |
| Score ≥ 3 |
The score aggregates major physiological and lifestyle predictors of haemorrhage. Hypertension and prior stroke reflect underlying vascular fragility, while renal/liver dysfunction impairs coagulation factor synthesis and drug clearance.
A high HAS-BLED score is NOT a reason to withhold anticoagulation. Instead, it identifies the patient who needs more frequent monitoring and more aggressive management of modifiable risks. In most high-risk patients, the benefit of stroke prevention still far outweighs the risk of major bleeding.
While HAS-BLED is mnemonic-based and easy to use at the bedside, newer biomarker-based scores like the ABC (Age, Biomarkers, Clinical history) score are now considered more accurate if hs-Troponin and GDF-15 are available.
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation.
Formally recommended by the European Society of Cardiology (ESC) and several other international societies for routine bleeding risk assessment.
Dutch cardiologist who developed the score as part of his research into stroke prevention and bleeding risk in atrial fibrillation management.
The score was developed to replace older, more complex bleeding risk models that were difficult to use in daily clinical practice. HAS-BLED was specifically designed to be mnemonic-friendly.
